Adobe Digital Signature certified by SAFE-BioPharma

RELATED NEWS Adobe to release PDF for Industry Standardization Adobe releases major upgrade to RoboHelp Adobe named to FORTUNE's list of 100 Best Cos to Work For Adobe announces availability of Adobe Reader 8 Nifty BSE | NSE 25/05/12 Are Mutual Funds betting on Nifty?

Adobe Systems Incorporated (Nasdaq:ADBE) today announced that SAFE(Signatures and Authentication for Everyone) -BioPharma Association has certified Adobe® Acrobat® software, Adobe Reader® with Adobe LiveCycle® Reader Extensions and Adobe LiveCycle Document Security software for compliance the with the SAFE? Digital signature standard. These are the first software products ever certified by SAFE, a non-profit association that manages digital identity and signature standards for pharmaceutical industries.

 

With today's announcement, legally binding digital signatures are more readily available to biopharmaceutical professionals who need help eliminating the inefficiencies and inaccuracies of paper-based processes while improving end-to-end electronic document workflows. By using the Adobe products certified by SAFE, biopharmaceutical organizations, clinical investigators and regulators can collaborate more securely and efficiently to better service patients, conduct pharmaceutical research, and help bring new drugs to market more quickly.

 

"The successful certification by SAFE of these Adobe products is very important to ensure that SAFE compliance is guaranteed for product users," said Kay Bross, Senior PKI Specialist, Information Security and Solutions, Procter & Gamble Co. "As Procter & Gamble moves forward to implement SAFE signatures within the enterprise, the utilization of SAFE-compliant tools

will offer a stable delivery mechanism on which to build a platform of electronic business transactions."

 

"SAFE congratulates Adobe on being the first company to invest in our certification program. We expect these readily available certified products to accelerate use of SAFE digital signatures in the pharmaceutical industry," said Mollie Shields-Uehling, President and Chief Executive Officer, SAFE-BioPharma Association.

 

Contd on page 2.....